Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Athira Pharma, Inc. (ATHA : NSDQ)

• Company Description    Athira Pharma Inc. is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. Athira Pharma Inc. is based in SEATTLE. Number of Employees: 26

• Price / Volume Information    Yesterday's Closing Price: $0.39 Daily Weekly Monthly 20 Day Moving Average: 232,104 shares Shares Outstanding: 39.04 (millions) Market Capitalization: $15.34 (millions) Beta: 2.99 52 Week High: $3.67 52 Week Low: $0.22 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 26.77% 20.40% 12 Week 29.28% 12.60% Year To Date -33.01% -37.44%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 18706 North Creek Parkway Suite 104 - Bothell,WA 98011 USA ph: 425-620-8501 fax: - ir@athira.com http://www.athira.com

• General Corporate Information    Officers Mark Litton - President; Chief Executive Officer and Director Kelly A. Romano - Chairwoman of the Board of Directors Robert Renninger - Senior Vice President; Finance and Accounting Joseph Edelman - Director James A. Johnson - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 04746L104 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/07/25 Share - Related Items Shares Outstanding: 39.04 Most Recent Split Date: (:1) Beta: 2.99 Market Capitalization: $15.34 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/07/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.41 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 66.67% vs. Previous Quarter: 41.03% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -142.99 12/31/24 - -132.57 ROA 06/30/25 - - 03/31/25 - -106.40 12/31/24 - -99.49 Current Ratio 06/30/25 - - 03/31/25 - 7.26 12/31/24 - 4.18 Quick Ratio 06/30/25 - - 03/31/25 - 7.26 12/31/24 - 4.18 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.96 12/31/24 - 1.16 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©